Latest News and Press Releases

Vertero appoints Jeffrey Kasten as Chief Business Officer to drive strategic partnerships and accelerate portfolio strategy in neurodegenerative diseases.

Vertero announces initiation of Phase 1 study of VT-5006, a first-in-class selective small molecule therapy for Parkinson’s disease.

Vertero unveils new strategic direction, promising lead asset targeting peripheral drivers of Parkinson’s disease, and Series D financing.

Espoo, Finland, 21 August 2025: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop Parkinson’s disease, releases today the Company’s 1H 2025...

NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor Phase 1b/2a study results published in Movement Disorders journalOral,...

Montara Therapeutics received a research grant from The Michael J. Fox Foundation for the development of new therapies targeting LRRK2.

Inflammasome-driven microglial inflammation key to accumulation of toxic phosphorylated alpha-synuclein leading to neurodegeneration and Parkinson's.

ZyVersa's IC 100 blocked microglial NLRP1 inflammasome activation and reduced alpha-synuclein accumulation supporting its potential for Parkinson's Disease

New York, USA, April 22, 2025 (GLOBE NEWSWIRE) -- Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight ...

AGOURA HILLS, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...